1612171-82-0

Basic information

• Product Name: 2-bromo-N-isopropyl-5-nitropyridin-4-amine
• Synonyms: 2-bromo-N-isopropyl-5-nitropyridin-4-amine
• CAS NO: 1612171-82-0
• Molecular Weight: 260.09
• Mol File: 1612171-82-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-bromo-N-isopropyl-5-nitropyridin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-N-isopropyl-5-nitropyridin-4-amine(1612171-82-0)
• EPA Substance Registry System: 2-bromo-N-isopropyl-5-nitropyridin-4-amine(1612171-82-0)

Safety Data

• Hazardous Substances Data: 1612171-82-0(Hazardous Substances Data)

Upstream product

• 4487-57-4 2,4-dibromo-5-nitropyridine 
• 75-31-0 isopropylamine 

Downstream Products

• 1612172-56-1 benzyl N-((1R,5S,6s)-3-(4-((1-isopropyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)pyrimidin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)carbamate 
• 1612164-58-5 N²-(1-benzyl-1H-pyrazol-3-yl)-N₄-(1-isopropyl-1H-imidazo[4,5-c]pyridin-6-yl)pyrimidine-2,4-diamine 

Relevant articles and documents

EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand which binds to an E3 ubiquitin ligase and on the other end a moiety which binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effectuate ubiquitination, and therefore, degradation (and inhibition) of the target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS

This invention relates to novel compounds of formula (I) which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer. (Formula I)